BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25745997)

  • 1. Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth.
    Noy PJ; Lodhia P; Khan K; Zhuang X; Ward DG; Verissimo AR; Bacon A; Bicknell R
    Oncogene; 2015 Nov; 34(47):5821-31. PubMed ID: 25745997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
    Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
    Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sprouting angiogenesis is regulated by shedding of the C-type lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboid-like 2 protein (RHBDL2).
    Noy PJ; Swain RK; Khan K; Lodhia P; Bicknell R
    FASEB J; 2016 Jun; 30(6):2311-23. PubMed ID: 26939791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
    Kim TK; Park CS; Jang J; Kim MR; Na HJ; Lee K; Kim HJ; Heo K; Yoo BC; Kim YM; Lee JW; Kim SJ; Kim ES; Kim DY; Cha K; Lee TG; Lee S
    Mol Oncol; 2018 Mar; 12(3):356-372. PubMed ID: 29316206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.
    Ki MK; Jeoung MH; Choi JR; Rho SS; Kwon YG; Shim H; Chung J; Hong HJ; Song BD; Lee S
    Oncogene; 2013 Nov; 32(48):5449-57. PubMed ID: 23644659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers.
    Zanivan S; Maione F; Hein MY; Hernández-Fernaud JR; Ostasiewicz P; Giraudo E; Mann M
    Mol Cell Proteomics; 2013 Dec; 12(12):3599-611. PubMed ID: 23979707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis.
    Jang J; Kim MR; Kim TK; Lee WR; Kim JH; Heo K; Lee S
    Sci Rep; 2017 Sep; 7(1):10666. PubMed ID: 28878328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis.
    Lee S; Rho SS; Park H; Park JA; Kim J; Lee IK; Koh GY; Mochizuki N; Kim YM; Kwon YG
    J Clin Invest; 2017 Feb; 127(2):457-471. PubMed ID: 27991863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway.
    Lorenzon E; Colladel R; Andreuzzi E; Marastoni S; Todaro F; Schiappacassi M; Ligresti G; Colombatti A; Mongiat M
    Oncogene; 2012 Jun; 31(26):3136-47. PubMed ID: 22020326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis.
    Andreuzzi E; Colladel R; Pellicani R; Tarticchio G; Cannizzaro R; Spessotto P; Bussolati B; Brossa A; De Paoli P; Canzonieri V; Iozzo RV; Colombatti A; Mongiat M
    Matrix Biol; 2017 Dec; 64():40-53. PubMed ID: 28435016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clec14a genetically interacts with Etv2 and Vegf signaling during vasculogenesis and angiogenesis in zebrafish.
    Pociute K; Schumacher JA; Sumanas S
    BMC Dev Biol; 2019 Apr; 19(1):6. PubMed ID: 30953479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth.
    Zhuang X; Maione F; Robinson J; Bentley M; Kaul B; Whitworth K; Jumbu N; Jinks E; Bystrom J; Gabriele P; Garibaldi E; Delmastro E; Nagy Z; Gilham D; Giraudo E; Bicknell R; Lee SP
    JCI Insight; 2020 Oct; 5(19):. PubMed ID: 33004686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLEC14A deficiency exacerbates neuronal loss by increasing blood-brain barrier permeability and inflammation.
    Kim Y; Lee S; Zhang H; Lee S; Kim H; Kim Y; Won MH; Kim YM; Kwon YG
    J Neuroinflammation; 2020 Feb; 17(1):48. PubMed ID: 32019570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours.
    Robinson J; Whitworth K; Jinks E; Nagy Z; Bicknell R; Lee SP
    J Pathol Clin Res; 2020 Oct; 6(4):308-319. PubMed ID: 32696621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A.
    Mura M; Swain RK; Zhuang X; Vorschmitt H; Reynolds G; Durant S; Beesley JF; Herbert JM; Sheldon H; Andre M; Sanderson S; Glen K; Luu NT; McGettrick HM; Antczak P; Falciani F; Nash GB; Nagy ZS; Bicknell R
    Oncogene; 2012 Jan; 31(3):293-305. PubMed ID: 21706054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
    Khan KA; McMurray JL; Mohammed F; Bicknell R
    FEBS J; 2019 Sep; 286(17):3299-3332. PubMed ID: 31287944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion.
    Rho SS; Choi HJ; Min JK; Lee HW; Park H; Park H; Kim YM; Kwon YG
    Biochem Biophys Res Commun; 2011 Jan; 404(1):103-8. PubMed ID: 21095181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium.
    Galvagni F; Nardi F; Spiga O; Trezza A; Tarticchio G; Pellicani R; Andreuzzi E; Caldi E; Toti P; Tosi GM; Santucci A; Iozzo RV; Mongiat M; Orlandini M
    Matrix Biol; 2017 Dec; 64():112-127. PubMed ID: 28912033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics-based screening of the endothelial heparan sulfate interactome reveals that C-type lectin 14a (CLEC14A) is a heparin-binding protein.
    Sandoval DR; Gomez Toledo A; Painter CD; Tota EM; Sheikh MO; West AMV; Frank MM; Wells L; Xu D; Bicknell R; Corbett KD; Esko JD
    J Biol Chem; 2020 Feb; 295(9):2804-2821. PubMed ID: 31964714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo.
    Jin K; He K; Teng F; Li G; Wang H; Han N; Xu Z; Cao J; Wu J; Yu D; Teng L
    Clin Transl Oncol; 2011 Dec; 13(12):878-84. PubMed ID: 22126731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.